Heterologous cells cooperate to augment stem cell migration, homing, and engraftment.
T-lymphocyte depletion of bone marrow grafts compromises engraftment, suggesting a facilitating mechanism provided by the T cells that has been shown to associate with CD8(+) but not CD4(+) T cells. Explanations for this phenomenon have focused on immune targeting of residual host cells or cytokine production. We provide evidence for an alternative mechanism based on cooperative effects on cell motility. We observed that engraftment of CD34(+) cells in a beta(2)-microglobulin-deficient nonobese diabetic/severe combined immunodeficiency (beta(2)m(-/-) NOD/SCID) mouse model paralleled clinical observations in humans, with an enhancing effect noted from the addition of CD8(+) cells but not CD4(+) cells. This correlated with CD8(+) augmentation of CD34(+) cell homing to the bone marrow in vivo and CD8(+) cell-associated increases of CD34(+) cell transmigration through a bone marrow endothelial cell line in vitro. The cooperative interaction was not sensitive to brefeldin A inhibition of protein secretion. However, cytochalasin D-induced inhibition of CD8(+) cytoskeletal rearrangements abrogated CD34(+) transendothelial migration and impaired CD34(+) cell homing in vivo. CD8(+) cells did not migrate in tandem with CD34(+) cells or alter endothelial barrier integrity; rather, they affected phosphotyrosine-mediated signaling in CD34(+) cells in response to the chemokine stromal derived factor-1alpha (SDF-1alpha). These data demonstrate cell-cell cooperativity between different cell types in mediating chemotactic events and provide one potential explanation for the clinically observed effect of CD8(+) cells on bone marrow transplantation. This modification of cell migration by neighboring cells provides broad possibilities for combinatorial effects between cells of different types to influence cell localization.
Adams
Gregor B
GB
Partners AIDS Research Center and MGH Cancer Center, Harvard Medical School, Massachusetts General Hospital, Boston 02129, USA.
Chabner
Karissa T
KT
Foxall
Russell B
RB
Weibrecht
Kathryn W
KW
Rodrigues
Neil P
NP
Dombkowski
David
D
Fallon
Robert
R
Poznansky
Mark C
MC
Scadden
David T
DT
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology / Q000637:transplantation* / Q000648:ultrastructure; D002450:Cell Communication; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000502:physiology; D002633:Chemotaxis; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D003599:Cytoskeleton / Q000648:ultrastructure; D006085:Graft Survival; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D008212:Lymphocyte Depletion / Q000009:adverse effects / Q000379:methods; D051379:Mice; D018345:Mice, Knockout; D019718:Receptors, CXCR4 / Q000502:physiology; D015398:Signal Transduction; D014183:Transplantation, Heterologous
C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; C515256:Cxcl12 protein, mouse; D019718:Receptors, CXCR4